Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, curren... Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. The company was incorporated in 2005 and is based in Rosebery, Australia. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.025 | 25 | 0.1 | 0.125 | 0.1 | 214774 | 0.11314017 | DE |
| 4 | 0 | 0 | 0.125 | 0.125 | 0.09 | 126732 | 0.10966882 | DE |
| 12 | 0 | 0 | 0.125 | 0.15 | 0.09 | 91976 | 0.1125888 | DE |
| 26 | -0.04 | -24.2424242424 | 0.165 | 0.2 | 0.09 | 75805 | 0.1271869 | DE |
| 52 | 0.08 | 177.777777778 | 0.045 | 0.455 | 0.037 | 75514 | 0.14759643 | DE |
| 156 | -0.29 | -69.8795180723 | 0.415 | 0.5 | 0.037 | 67714 | 0.15052276 | DE |
| 260 | -0.805 | -86.5591397849 | 0.93 | 2.2 | 0.037 | 48977 | 0.42120077 | DE |
theRupertPupkin
3分前
rmmc
3分前
Thomas@yahoo
4分前
barnstormer
4分前
Real McCoy
4分前
jimr1717
7分前
snupoled
7分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。